Evaluation Of Eslicarbazepine In The Management Of Partial Seizures - Dixit, Dirghayu
36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Eslicarbazepine is a novel adds on therapy introduced in Indian market in April 2011 in the management of partial seizures. Despite of having a strong pool of evidences & EMEA approval, this molecule in-clinic usage is not as per expectations. Through this research work, we intend to make an attempt to understand underlying psychological & environmental (peer group effect) factors restricting the potential of molecule. The major emphasize of my work was to "EVALUATION OF IN - CLINIC USAGE OF ESLICARBAZEPINE IN THE MANAGEMENT OF PARTIAL SEIZURES" This project gave me immense opportunities to…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Eslicarbazepine is a novel adds on therapy introduced in Indian market in April 2011 in the management of partial seizures. Despite of having a strong pool of evidences & EMEA approval, this molecule in-clinic usage is not as per expectations. Through this research work, we intend to make an attempt to understand underlying psychological & environmental (peer group effect) factors restricting the potential of molecule. The major emphasize of my work was to "EVALUATION OF IN - CLINIC USAGE OF ESLICARBAZEPINE IN THE MANAGEMENT OF PARTIAL SEIZURES" This project gave me immense opportunities to upgrade my knowledge related to marketing field and also gave me a chance to learn and understand the strategies to be kept in mind while making a new molecule for AED's.
Autorenporträt
Dirghayu Dixit recevied his bachelor's degree in pharmacy in 2011 from Gujarat University, Ahmedabad,Master's degree in MBA(Pharmaceutical Management) in 2013 from Kadi Serva Vishwavidyalaya, Gandhinagar.He Completed 2 Years of Experience in Pharmaceutical Marketing.